慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择*

doi:10.3969/j.issn.1672-5069.2023.05.002

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (5): 612-614.doi: 10.3969/j.issn.1672-5069.2023.05.002

慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*

张丹, 丁洋

110022 沈阳市中国医科大学附属盛京医院感染病科

收稿日期:2023-07-03 出版日期:2023-09-10 发布日期:2023-09-13
通讯作者: 丁洋,E-mail:yding0903@sina.com
作者简介:张丹,女,47岁,医学博士,主治医师。E-mail:zd960422@aliyun.com
基金资助:
^*辽宁省科技厅应用基础研究计划项目(编号:2022JH2/101500009)

Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection

Zhang Dan, Ding Yang

Department of Infectious Diseases,Shengjing Hospital, China Medical University,Shenyang 110022,China

Received:2023-07-03 Online:2023-09-10 Published:2023-09-13

摘要/Abstract

关键词: 慢性乙型肝炎, 病毒载量, 低病毒血症, 治疗策略

Key words: Hepatitis B, Viral loads, Low-level viremia, Anti-viral strategies

张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.

Zhang Dan, Ding Yang. Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection[J]. Journal of Practical Hepatology, 2023, 26(5): 612-614.

参考文献

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[2] Yuan J, Lu ZK, Xiong X,et al. Impact of national volume-based procurement on the procurement volumes and spending for antiviral medications of hepatitis B virus. Front Pharmacol, 2022, 13:842944.
[3] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志, 2022, 30(2): 131-136.
[4] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[5] Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology, 2013, 58(2):505-513.
[6] Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3):185-195.
[7] Lin MH, Li HQ, Zhu L, et al. Liver fibrosis in the natural course of chronic hepatitis B viral infection: a systematic review with meta-analysis. Dig Dis Sci, 2022, 67(6):2608-2626.
[8] Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut, 2018, 67(5):945-952.
[9] 赵素贤, 常楚笛, 南月敏. 精准免疫分期指导慢性HBV感染者尽早启动抗病毒治疗. 中华肝脏病杂志, 2023, 31(3):228-232.
[10] Lee H, Jang S, Ahn SH, et al. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level<2000 IU/mL. Hepatol Int, 2022,16(2):294-305.
[11] Huang DQ, Tamaki N, Lee HW, et al. Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis. Hepatology, 2023, 77(5):1746-1756.
[12] Wong RJ, Kaufman HW, Niles JK, et al. Simplifying treatment criteria in chronic hepatitis B: reducing barriers to elimination. Clin Infect Dis, 2023, 76(3):e791-e800.
[13] Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 2006, 354(10):1001-1010.
[14] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68(4):672-681.
[15] Buti M, Gane E, Seto WK, et al. TAF vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016,1(3):196-206.
[16] Chan HL, Fung S, Seto WK, et al. TAF vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol,2016, 1(3):185-195.
[17] Liu Z, Jin Q, Zhang Y,et al. 96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. J Clin Transl Hepatol, 2023, 11(3):649-660.
[18] Ning Q, Han M, Sun Y, et al. Switching from entecavir to pegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014, 61(4):777-784.
[19] Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol, 2018, 6(1): 25-34.
[20] 程齐齐, 杨丽霞, 蔡天盼,等. 核苷(酸)类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志, 2022, 38(12): 2716-2722.
[21] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection withlow level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol, 2021, 9(6):850-859.
[22] Sun Y, Wu X, Zhou J,et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol, 2020, 18(11):2582-2591,e6.
[23] Kim JH, Sinn DH, Kang W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66(2):335-343.
[24] Lee SB, Jeong J, Park JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020,26(3):364-375.
[25] Zhang Q, Cai DC, Hu P,et al. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl), 2021, 134(23):2810-2817.
[26] Li ZB, Li L, Niu XX,et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021, 41(6):1254-1264.

慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*

Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.
[2]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[3]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[4]	郝岸华, 杜忠彩, 周林, 马磊. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 630-633.
[5]	刘爱华, 符建, 陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 634-637.
[6]	周克丽, 吕晓丽, 周洋, 龙浩成. 应用肝脏硬度检测联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 480-483.
[7]	焦宇兵, 李灵, 黄新辉, 谢义星, 吴为敏, 翁吓俤, 郭武华. 核苷(酸)类似物抗病毒治疗HBV相关肝细胞癌患者低病毒血症及其对肿瘤治疗疗效的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 548-551.
[8]	刘莹, 陈东妙, 王从容. 慢性乙型肝炎、乙型肝炎肝硬化和原发性肝癌患者血清腺苷脱氨酶、α-L-岩藻糖苷酶和AFP-L3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 552-555.
[9]	陶贞贞, 王永莉, 孙红艳, 王慧芬. 二维剪切波弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 328-331.
[10]	赵景, 何秀波, 谌瑾寰. 肝脏剪切波弹性成像联合GGT/PLT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 332-335.
[11]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[12]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[13]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[14]	方慧晶, 朱传龙, 章莉莉. 宿主靶向抗乙型肝炎病毒治疗策略研究新进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 449-452.
[15]	符鑫, 刘悦, 彭鑫, 黄婷婷, 廖雪霞, 颜悦蓉. 采用高敏检测技术检测血清HBV DNA载量筛选低病毒血症的无偿献血人群隐匿性乙型肝炎病毒感染研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 169-172.